1. Bauer DC, Black D, Ensrud K, Thompson D, Hochberg M, Nevitt M, Musliner T, Freedholm D (2000) Upper gastrointestinal tract safety profile of alendronate: the fracture intervention trial. Arch Intern Med 160:517–525
2. Black DM, Arden NK, Palermo L, Pearson J, Cummings SR (1999) Prevalent vertebral deformities predict hip fractures and new vertebral deformities but not wrist fractures. Study of Osteoporotic Fractures Research Group. J Bone Miner Res 14:821–828
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541
4. Black DM, Thompson DE, Bauer D, Hochberg M, Ensrud K, Musliner TA, Yates J, Cummings SR (2000) The early antifracture effect of alendronate in women with osteoporosis: results from the fracture intervention trial. Bone 26(suppl):B24
5. Castell DO (1996) „Pill esophagitis“-the case of alendronate. N Engl J Med 335:1058–1059